XERS
HealthcareXeris Biopharma Holdings, Inc. · Biotechnology · $1B
What is Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings is a Chicago-based biopharmaceutical company focused on commercializing specialty therapies in endocrinology, neurology, and gastroenterology. It combines a growing marketed product portfolio with proprietary formulation technology platforms.
Xeris generates revenue by marketing three approved products targeting rare and underserved conditions. The company also advances a pipeline of development programs that leverage its proprietary XeriSol and XeriJect formulation platforms to extend existing products into new indications and bring novel therapies to market. Its commercial focus spans severe hypoglycemia, primary periodic paralysis, and Cushing's syndrome — conditions with limited treatment options and defined patient populations.
Xeris Biopharma was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Gvoke — ready-to-use liquid glucagon for severe hypoglycemia
- Keveyis — therapy for primary periodic paralysis variants
- Recorlev — cortisol synthesis inhibitor for Cushing's syndrome
- XeriSol and XeriJect proprietary formulation technology platforms
- Pipeline programs extending approved products into new indications
Is XERS a Good Stock to Buy?
UQS Score rates XERS as Below Average overall.
The standout element in Xeris's profile is its Growth pillar, rated Strong — reflecting meaningful commercial momentum across its marketed product portfolio. Risk is rated Neutral, suggesting the company's risk profile is neither particularly alarming nor especially reassuring relative to small-cap biopharma peers.
Quality and Moat are both rated Weak, pointing to limited earnings durability and a narrow competitive advantage. Valuation is rated Elevated, meaning the current market price may already reflect optimistic assumptions about future growth.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does XERS pay dividends?
No — Xeris Biopharma Holdings, Inc. does not currently pay a dividend.
Xeris Biopharma does not currently pay a dividend. This is typical for small-cap biopharmaceutical companies at Xeris's stage, where available capital is directed toward commercializing existing products, funding pipeline development, and scaling the business rather than returning cash to shareholders.
When does XERS report earnings?
Xeris Biopharma reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have reflected the ongoing commercial ramp of Gvoke, Keveyis, and Recorlev. As a growth-stage specialty biopharma, quarterly results are closely watched for product revenue trajectory and operating expense management.
For the most recent quarter's results and guidance, visit Xeris Biopharma's investor relations page directly.
XERS Price History
+88.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Xeris Biopharma Holdings, Inc.?
Based on Xeris Biopharma Holdings, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
XERS Long-term Outlook
Xeris's Strong Growth pillar suggests the company's commercial products are gaining traction, and the pipeline offers potential for incremental revenue over time. However, the Weak Quality and Moat ratings indicate that converting top-line growth into durable profitability remains a challenge. The Elevated Valuation pillar adds a layer of caution — the market may already be pricing in a favorable growth trajectory, leaving limited room for execution shortfalls.
Growth drivers
- Continued commercial uptake of Gvoke, Keveyis, and Recorlev in specialty markets
- Pipeline expansion leveraging XeriSol and XeriJect platforms into new indications
- Rare disease focus with limited competition in defined patient populations
Key risks
- Weak Quality and Moat ratings suggest limited pricing power and earnings durability
- Elevated Valuation leaves little margin of safety if growth disappoints
- Small-cap biopharma funding and execution risk in a competitive specialty pharma landscape
XERS vs Peers
Xeris operates in a niche specialty biopharma space alongside several small-cap peers focused on underserved therapeutic areas.
UroGen focuses on urology-specific oncology therapies, differentiating itself from Xeris's endocrinology and neurology commercial focus.
ORIC is a clinical-stage oncology company, operating earlier in the development curve than Xeris's multi-product commercial stage.
Aktis pursues targeted radiotherapy in oncology, a distinct modality and therapeutic area compared to Xeris's hormone and metabolic disorder portfolio.
Frequently Asked Questions
What does Xeris Biopharma do?
Xeris Biopharma is a specialty biopharmaceutical company that markets approved therapies for rare and underserved conditions in endocrinology, neurology, and gastroenterology. Its three commercial products — Gvoke, Keveyis, and Recorlev — address severe hypoglycemia, primary periodic paralysis, and Cushing's syndrome respectively. The company also develops pipeline programs using its proprietary XeriSol and XeriJect formulation platforms.
Does XERS pay dividends?
No, Xeris Biopharma does not currently pay a dividend. The company is in a commercial growth phase and directs capital toward product commercialization and pipeline development rather than shareholder distributions. This is common among small-cap specialty biopharma companies at a similar stage.
When does XERS report earnings?
Xeris Biopharma reports financial results on a quarterly cadence, in line with standard US-listed company practice. For the most up-to-date earnings schedule and recent results, check the investor relations section of the Xeris Biopharma website directly.
Is XERS a good stock to buy?
UQS Score rates XERS as Below Average overall. The Growth pillar is rated Strong, but Quality and Moat are both Weak, and Valuation is Elevated. That combination means growth momentum exists but durability and pricing concerns are present. The full pillar breakdown is available to UQS Pro members.
Is XERS overvalued?
The UQS Valuation pillar for XERS is rated Elevated, suggesting the current market price may reflect optimistic growth assumptions. Investors should weigh this against the Weak Quality and Moat ratings, which indicate limited earnings durability. The complete valuation analysis is available in the Pro member view.
How does XERS compare to its competitors?
Xeris is differentiated by its multi-product commercial stage and rare endocrinology focus. Peers like UroGen operate in urology oncology, while ORIC and Aktis are earlier-stage or oncology-focused companies. Xeris's combination of three marketed products and proprietary formulation platforms sets it apart within the small-cap specialty biopharma group.
What is XERS's market cap bracket?
Xeris Biopharma is classified as a small-cap company. This places it in a segment of the market characterized by higher growth potential but also greater volatility and execution risk compared to larger, more established pharmaceutical companies.
Who founded Xeris Biopharma?
Xeris Biopharma was incorporated in 2005 and has evolved through several stages to its current form as a publicly listed specialty biopharma company headquartered in Chicago, Illinois. Detailed founding history is widely available through the company's public filings and investor relations materials.
Is XERS a long-term quality investment?
From a long-term quality perspective, XERS presents a mixed picture. The Strong Growth pillar indicates commercial momentum, but Weak Quality and Moat ratings suggest the business has not yet established durable competitive advantages or consistent earnings power. Long-term quality indicators are best assessed through the full UQS pillar breakdown available to Pro members.
What is the main competitive advantage of Xeris Biopharma?
Xeris's primary differentiation lies in its proprietary XeriSol and XeriJect formulation technology platforms, which enable ready-to-use liquid formulations of drugs that are traditionally difficult to stabilize. This technology underpins its marketed products and pipeline, providing a degree of technical differentiation in specialty drug delivery.
What sector does XERS belong to?
Xeris Biopharma operates in the Healthcare sector, specifically within specialty and rare-disease biopharmaceuticals. Its therapeutic focus spans endocrinology, neurology, and gastroenterology — areas with defined unmet needs and relatively limited competition compared to broader pharmaceutical markets.
Is XERS a growth stock or value stock?
Based on UQS pillar ratings, XERS leans toward the growth side — the Growth pillar is rated Strong. However, the Elevated Valuation rating means it does not screen as a value opportunity. It is best characterized as a growth-stage specialty biopharma where the market has already priced in significant future progress.
Unlock Full XERS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓See how XERS ranks within the Healthcare sector
- ✓Compare XERS against peers on every quality dimension
- ✓Get the full analyst-style breakdown in one place
- ✓Track score changes as new data becomes available
Pro Analysis
XERS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 57.3 | 60.6 | 35.0 | 100.0 | 50.9 | 38.6 | 0.0 |
| May 22, 2026 | 57.3 | 60.3 | 35.0 | 100.0 | 50.9 | 38.6 | -0.2 |
| May 21, 2026 | 57.5 | 60.5 | 35.0 | 100.0 | 50.9 | 39.6 | +0.5 |
| May 13, 2026 | 57.0 | 60.3 | 35.0 | 100.0 | 50.9 | 36.9 | -0.4 |
| May 12, 2026 | 57.4 | 60.7 | 35.0 | 100.0 | 50.9 | 39.1 | +0.6 |
| May 10, 2026 | 56.8 | 60.1 | 35.0 | 100.0 | 50.9 | 36.2 | +6.1 |
| May 7, 2026 | 50.7 | 35.1 | 35.0 | 100.0 | 51.2 | 36.8 | -0.1 |
| May 3, 2026 | 50.8 | 35.1 | 35.0 | 100.0 | 51.2 | 37.5 | -0.3 |
| May 1, 2026 | 51.1 | 35.1 | 35.0 | 100.0 | 51.2 | 39.2 | 0.0 |
| Apr 26, 2026 | 51.1 | 35.1 | 35.0 | 100.0 | 51.2 | 39.5 | +0.3 |
XERS — Pillar Breakdown
Quality
— 60.6/100 (25%)Xeris Biopharma Holdings, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Xeris Biopharma Holdings, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 50.9/100 (15%)Xeris Biopharma Holdings, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 38.6/100 (15%)Xeris Biopharma Holdings, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 35/100 (25%)Xeris Biopharma Holdings, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for XERS.
Score Composition
Financial Data
More Stock Analysis
How is the XERS UQS Score Calculated?
The UQS (Unified Quality Score) for Xeris Biopharma Holdings, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Xeris Biopharma Holdings, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Xeris Biopharma Holdings, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.